JP2020505432A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020505432A5 JP2020505432A5 JP2019542186A JP2019542186A JP2020505432A5 JP 2020505432 A5 JP2020505432 A5 JP 2020505432A5 JP 2019542186 A JP2019542186 A JP 2019542186A JP 2019542186 A JP2019542186 A JP 2019542186A JP 2020505432 A5 JP2020505432 A5 JP 2020505432A5
- Authority
- JP
- Japan
- Prior art keywords
- item
- pharmaceutically acceptable
- acceptable salt
- pharmaceutical composition
- patient
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims description 60
- 239000008194 pharmaceutical composition Substances 0.000 claims description 40
- CXOXHMZGEKVPMT-UHFFFAOYSA-N clobazam Chemical compound O=C1CC(=O)N(C)C2=CC=C(Cl)C=C2N1C1=CC=CC=C1 CXOXHMZGEKVPMT-UHFFFAOYSA-N 0.000 claims description 14
- 229960001403 clobazam Drugs 0.000 claims description 14
- 208000009205 Tinnitus Diseases 0.000 claims description 11
- 231100000886 tinnitus Toxicity 0.000 claims description 11
- 238000001727 in vivo Methods 0.000 claims description 10
- 208000024891 symptom Diseases 0.000 claims description 7
- 210000005069 ears Anatomy 0.000 claims description 2
- 230000003068 static effect Effects 0.000 claims description 2
- ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 claims 5
- 229950004346 gaboxadol Drugs 0.000 claims 5
- 238000011260 co-administration Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 55
- 239000000203 mixture Substances 0.000 description 10
- 206010011878 Deafness Diseases 0.000 description 5
- 231100000895 deafness Toxicity 0.000 description 5
- 208000016354 hearing loss disease Diseases 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 3
- 208000027530 Meniere disease Diseases 0.000 description 2
- 206010011891 Deafness neurosensory Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000009966 Sensorineural Hearing Loss Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 208000023573 sensorineural hearing loss disease Diseases 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022163131A JP2023011630A (ja) | 2017-02-03 | 2022-10-11 | 耳鳴りの処置におけるガボキサドールの使用 |
| JP2024163596A JP2024178317A (ja) | 2017-02-03 | 2024-09-20 | 耳鳴りの処置におけるガボキサドールの使用 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762454280P | 2017-02-03 | 2017-02-03 | |
| US62/454,280 | 2017-02-03 | ||
| US201762530528P | 2017-07-10 | 2017-07-10 | |
| US62/530,528 | 2017-07-10 | ||
| US201762536669P | 2017-07-25 | 2017-07-25 | |
| US62/536,669 | 2017-07-25 | ||
| PCT/US2018/016602 WO2018144827A1 (en) | 2017-02-03 | 2018-02-02 | Use of gaboxadol in the treatment of tinnitus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022163131A Division JP2023011630A (ja) | 2017-02-03 | 2022-10-11 | 耳鳴りの処置におけるガボキサドールの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020505432A JP2020505432A (ja) | 2020-02-20 |
| JP2020505432A5 true JP2020505432A5 (OSRAM) | 2021-03-18 |
Family
ID=63038963
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019542186A Pending JP2020505432A (ja) | 2017-02-03 | 2018-02-02 | 耳鳴りの処置におけるガボキサドールの使用 |
| JP2022163131A Pending JP2023011630A (ja) | 2017-02-03 | 2022-10-11 | 耳鳴りの処置におけるガボキサドールの使用 |
| JP2024163596A Pending JP2024178317A (ja) | 2017-02-03 | 2024-09-20 | 耳鳴りの処置におけるガボキサドールの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022163131A Pending JP2023011630A (ja) | 2017-02-03 | 2022-10-11 | 耳鳴りの処置におけるガボキサドールの使用 |
| JP2024163596A Pending JP2024178317A (ja) | 2017-02-03 | 2024-09-20 | 耳鳴りの処置におけるガボキサドールの使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10071083B2 (OSRAM) |
| EP (1) | EP3576738B1 (OSRAM) |
| JP (3) | JP2020505432A (OSRAM) |
| KR (1) | KR20190112046A (OSRAM) |
| CN (1) | CN110402140A (OSRAM) |
| AU (1) | AU2018215363A1 (OSRAM) |
| BR (1) | BR112019015832A2 (OSRAM) |
| CA (1) | CA3051586A1 (OSRAM) |
| DK (1) | DK3576738T3 (OSRAM) |
| ES (1) | ES2930899T3 (OSRAM) |
| HU (1) | HUE060609T2 (OSRAM) |
| IL (1) | IL268210A (OSRAM) |
| MX (1) | MX393900B (OSRAM) |
| PE (1) | PE20191407A1 (OSRAM) |
| PL (1) | PL3576738T3 (OSRAM) |
| PT (1) | PT3576738T (OSRAM) |
| WO (1) | WO2018144827A1 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4541420A3 (en) | 2015-07-17 | 2025-06-25 | Ovid Therapeutics Inc. | Methods of treating developmental disorders with gaboxadol |
| JP2019524816A (ja) | 2016-08-11 | 2019-09-05 | オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | てんかん性障害の処置のための方法および組成物 |
| US10071083B2 (en) | 2017-02-03 | 2018-09-11 | Ovid Therapeutics Inc | Use of gaboxadol in the treatment of tinnitus |
| CA3113644A1 (en) | 2018-09-20 | 2020-03-26 | Ovid Therapeutics Inc. | Use of gaboxadol for the treatment of tourette syndrome, tics and stuttering |
| JP2022514194A (ja) | 2018-11-21 | 2022-02-10 | セルテゴ セラピューティクス インコーポレイテッド | 自殺のリスクを低減し、うつ病を迅速に軽減するためのガボキサドール |
| MX2021007224A (es) * | 2018-12-17 | 2021-09-23 | Ovid Therapeutics Inc | Uso de gaboxadol para el tratamiento del trastorno del sue?o vigilia que no es de 24 horas. |
| CN114786669A (zh) * | 2019-12-18 | 2022-07-22 | 奥维德医疗公司 | 用于1p36缺失综合征的治疗性治疗的加波沙朵 |
| EP4153549A2 (en) | 2020-05-20 | 2023-03-29 | Certego Therapeutics Inc. | Ring deuterated gaboxadol and its use for the treatment of psychiatric disorders |
| EP4299059A1 (en) | 2022-07-01 | 2024-01-03 | Labelic Analysis, S.L. | Composition for the treatment of tinnitus |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2830083A (en) | 1953-04-29 | 1958-04-08 | Allied Chem & Dye Corp | Production of aryloxy aliphatic carboxylic acids |
| US3947579A (en) | 1974-06-03 | 1976-03-30 | Nelson Research & Development Company | Method and composition for potentiating neuroleptic drugs |
| US4084000A (en) | 1975-07-16 | 1978-04-11 | Nelson Research And Development Company | Method of treating schizophrenia |
| US4138484A (en) | 1976-08-16 | 1979-02-06 | Nelson Research & Development Company | Method for treating schizophrenia and method and composition for potentiating neuroleptic drugs |
| US4129652A (en) | 1976-08-16 | 1978-12-12 | Nelson Research & Development Company | Method for potentiating neuroleptic drugs |
| DK270278A (da) | 1977-06-20 | 1978-12-21 | Krogsgaard Larsen P | Cycliske aminosyrer |
| US4362731A (en) | 1980-09-01 | 1982-12-07 | Sandoz Ltd. | Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof |
| US4353910A (en) | 1981-11-27 | 1982-10-12 | Kefalas A/S | Derivatives of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridine-3-one, pharmaceutical compositions and methods of treatment |
| DE19525598C2 (de) | 1995-07-13 | 1997-09-25 | Max Planck Gesellschaft | Schlafmittel |
| DE19526864A1 (de) | 1995-07-22 | 1997-01-23 | Labtec Gmbh | Hormonpflaster |
| US6461644B1 (en) | 1996-03-25 | 2002-10-08 | Richard R. Jackson | Anesthetizing plastics, drug delivery plastics, and related medical products, systems and methods |
| US5948433A (en) | 1997-08-21 | 1999-09-07 | Bertek, Inc. | Transdermal patch |
| US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| US6676961B1 (en) | 2002-03-06 | 2004-01-13 | Automated Carrier Technologies, Inc. | Transdermal patch assembly |
| EP1663218A1 (en) * | 2003-09-10 | 2006-06-07 | MERCK SHARP & DOHME LTD. | Use of gabaa receptor agonists for the treatment of hearing, vestibular and attention disorders, intention tremor and restless leg syndrome |
| GB0402118D0 (en) * | 2004-01-30 | 2004-03-03 | Merck Sharp & Dohme | Polymorphic forms of a GABAA agonist |
| US20080269278A1 (en) | 2004-04-02 | 2008-10-30 | H. Lundbeck A/S | Treatment of Impaired Respiratory Function with Gaboxadol |
| DE102005004343A1 (de) | 2005-01-25 | 2006-08-10 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Behandlung von Phantomphänomenen |
| US20080262029A1 (en) | 2005-04-29 | 2008-10-23 | H. Lundbeck A/S | Acid and Base Salt Forms of Gaboxadol |
| US20110046090A1 (en) | 2005-10-31 | 2011-02-24 | Braincells Inc. | Modulation of neurogenesis with gaba agents and gaba analogs |
| CA2625210A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| JP2010510314A (ja) | 2006-11-22 | 2010-04-02 | シーサイド セラピューティクス，エルエルシー | 精神遅滞、ダウン症候群、脆弱ｘ症候群および自閉症の治療方法 |
| WO2008095221A1 (en) | 2007-02-07 | 2008-08-14 | Gosforth Centre (Holdings) Pty Ltd | Treatment of adhd |
| US20090143335A1 (en) | 2007-10-29 | 2009-06-04 | H. Lundbeck A/S | Modified absorption formulation of gaboxadol |
| DE102007063210A1 (de) | 2007-12-20 | 2009-06-25 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Arzneimittel zur Behandlung von Phantomphänomenen |
| WO2009082039A1 (en) * | 2007-12-26 | 2009-07-02 | Eisai R & D Management Co., Ltd. | Ampa receptor antagonists for epilepsy, mental disorders or deficits in sensory organ |
| US9089531B2 (en) | 2010-09-28 | 2015-07-28 | The Regents Of The University Of California | GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes |
| WO2012075286A2 (en) | 2010-12-01 | 2012-06-07 | The Regents Of The University Of California | Intrapulmonary benzodiazepine for the treatment and prevention of seizures |
| EP3108876A1 (en) | 2011-10-13 | 2016-12-28 | Jaleva Pharmaceuticals LLC | Methods and compositions for rapid transbuccal delivery of active agents |
| WO2014085668A1 (en) | 2012-11-30 | 2014-06-05 | The Regents Of The University Of California | Anticonvulsant activity of steroids |
| WO2014123909A1 (en) | 2013-02-05 | 2014-08-14 | University Of Washington Through Its Center For Commercialization | Positive allosteric modulators of the gaba-a receptor in the treatment of autism |
| SMT202100340T1 (it) | 2014-06-06 | 2021-07-12 | Ovid Therapeutics Inc | Metodi per aumentare l'inibizione tonica e trattare l'insonnia secondaria |
| ES2664810T3 (es) | 2014-06-12 | 2018-04-23 | Pfizer Limited | Derivados de imidazopiridazina como moduladores de la actividad del receptor GABAA |
| US20170348232A1 (en) | 2016-06-07 | 2017-12-07 | Ovid Therapeutics Inc. | Formulations of gaboxadol for treatment of angelman syndrome, fragile x syndrome and fragile x-associated tremor/ataxia syndrome |
| US9682069B2 (en) | 2015-07-17 | 2017-06-20 | Ovid Therapeutics Inc | Methods of treating Dravet syndrome |
| EP4541420A3 (en) * | 2015-07-17 | 2025-06-25 | Ovid Therapeutics Inc. | Methods of treating developmental disorders with gaboxadol |
| CA2994952A1 (en) | 2015-08-11 | 2017-02-16 | Ovid Therapeutics Inc. | Methods of sedation and parenteral formulation for use during critical care treatment |
| US9399034B1 (en) | 2015-08-11 | 2016-07-26 | Ovid Therapeutics Inc | Methods of sedation during critical care treatment |
| US9351968B1 (en) | 2015-09-09 | 2016-05-31 | Ovid Therapeutics Inc | Methods of treating developmental disorders using pipradrol |
| JP2019524816A (ja) | 2016-08-11 | 2019-09-05 | オービッド・セラピューティクス・インコーポレイテッドＯｖｉｄ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | てんかん性障害の処置のための方法および組成物 |
| US10071083B2 (en) | 2017-02-03 | 2018-09-11 | Ovid Therapeutics Inc | Use of gaboxadol in the treatment of tinnitus |
| JP2022514194A (ja) * | 2018-11-21 | 2022-02-10 | セルテゴ セラピューティクス インコーポレイテッド | 自殺のリスクを低減し、うつ病を迅速に軽減するためのガボキサドール |
-
2018
- 2018-01-17 US US15/873,425 patent/US10071083B2/en active Active
- 2018-02-02 HU HUE18747812A patent/HUE060609T2/hu unknown
- 2018-02-02 CN CN201880017336.5A patent/CN110402140A/zh active Pending
- 2018-02-02 MX MX2019009190A patent/MX393900B/es unknown
- 2018-02-02 EP EP18747812.8A patent/EP3576738B1/en active Active
- 2018-02-02 JP JP2019542186A patent/JP2020505432A/ja active Pending
- 2018-02-02 AU AU2018215363A patent/AU2018215363A1/en not_active Abandoned
- 2018-02-02 PE PE2019001533A patent/PE20191407A1/es unknown
- 2018-02-02 PL PL18747812.8T patent/PL3576738T3/pl unknown
- 2018-02-02 CA CA3051586A patent/CA3051586A1/en active Pending
- 2018-02-02 WO PCT/US2018/016602 patent/WO2018144827A1/en not_active Ceased
- 2018-02-02 KR KR1020197024876A patent/KR20190112046A/ko not_active Abandoned
- 2018-02-02 ES ES18747812T patent/ES2930899T3/es active Active
- 2018-02-02 BR BR112019015832-4A patent/BR112019015832A2/pt not_active IP Right Cessation
- 2018-02-02 DK DK18747812.8T patent/DK3576738T3/da active
- 2018-02-02 PT PT187478128T patent/PT3576738T/pt unknown
- 2018-08-07 US US16/056,754 patent/US10188635B2/en active Active
- 2018-12-12 US US16/217,291 patent/US20190111033A1/en not_active Abandoned
-
2019
- 2019-07-22 IL IL268210A patent/IL268210A/en unknown
-
2022
- 2022-10-11 JP JP2022163131A patent/JP2023011630A/ja active Pending
-
2024
- 2024-09-20 JP JP2024163596A patent/JP2024178317A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020505432A5 (OSRAM) | ||
| RU2006138153A (ru) | Способы лечения шума в ушах, индуцированного улитковой экситотоксичностью | |
| JP2020503269A5 (OSRAM) | ||
| RU2010150863A (ru) | Фармацевтическая композиция для лечения ушных заболеваний | |
| JP2011529854A5 (OSRAM) | ||
| AU2018357775B2 (en) | New combination of active agents for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD) | |
| KR101900520B1 (ko) | 복합 조성물 | |
| JP2017506624A5 (OSRAM) | ||
| JP2020533302A5 (OSRAM) | ||
| JP2005535691A5 (OSRAM) | ||
| JP2020536121A5 (OSRAM) | ||
| JP2011500589A5 (OSRAM) | ||
| JP2019507786A5 (OSRAM) | ||
| WO2018004576A3 (en) | A fast acting orally disintegrating film for administration of local anesthesia | |
| US11744833B2 (en) | Pharmaceutical compositions and methods for treatment of insomnia | |
| JP2019516727A5 (OSRAM) | ||
| Ryan et al. | Immunological damage to the inner ear: current and future therapeutic strategies | |
| Kim et al. | Hypersensitivity reaction to intravitreal clindamycin therapy | |
| TW201841635A (zh) | 用於治療抑鬱症之組合物及方法 | |
| JP2018502168A5 (OSRAM) | ||
| MX2022006523A (es) | Composicion que comprende budesonida para uso oftalmico. | |
| Shmidt | Glatiramer acetate is a first-line dual-action drug for the treatment of relapsing-remitting multiple sclerosis | |
| Ramchandani et al. | Pseudophakic macular edema in a steroid responder treated successfully with intravitreal methotrexate: A case report | |
| Chaudhary et al. | 2 What’s Bugging You? Alliaceous Therapy for Ekbom Syndrome | |
| CN103635194A (zh) | 用于治疗早泄的药物组合物以及用于治疗早泄的方法 |